Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $64000.0.

  • NewAmsterdam Pharma's Depreciation & Amortization (CF) rose 12857.14% to $64000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $212000.0, marking a year-over-year increase of 18266.67%. This contributed to the annual value of $113000.0 for FY2024, which is 13061.22% up from last year.
  • Latest data reveals that NewAmsterdam Pharma reported Depreciation & Amortization (CF) of $64000.0 as of Q3 2025, which was up 12857.14% from $45000.0 recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Depreciation & Amortization (CF) ranged from a high of $64000.0 in Q3 2025 and a low of $9000.0 during Q1 2023
  • For the 3-year period, NewAmsterdam Pharma's Depreciation & Amortization (CF) averaged around $31000.0, with its median value being $23500.0 (2024).
  • Examining YoY changes over the last 5 years, NewAmsterdam Pharma's Depreciation & Amortization (CF) showed a top increase of 29230.77% in 2024 and a maximum decrease of 6666.67% in 2024.
  • NewAmsterdam Pharma's Depreciation & Amortization (CF) (Quarter) stood at $13000.0 in 2023, then skyrocketed by 292.31% to $51000.0 in 2024, then rose by 25.49% to $64000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $64000.0 for Q3 2025, versus $45000.0 for Q2 2025 and $52000.0 for Q1 2025.